A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging 24-Week Study to Evaluate the Safety and Efficacy of a Single Injection of CNTX-4975 in Subjects With Chronic, Moderate to Severe Osteoarthritis Knee Pain

Trial Profile

A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging 24-Week Study to Evaluate the Safety and Efficacy of a Single Injection of CNTX-4975 in Subjects With Chronic, Moderate to Severe Osteoarthritis Knee Pain

Completed
Phase of Trial: Phase II

Latest Information Update: 16 Jul 2017

At a glance

  • Drugs Capsaicin (Primary)
  • Indications Pain
  • Focus Therapeutic Use
  • Acronyms TRIUMPH
  • Sponsors Centrexion Therapeutics
  • Most Recent Events

    • 17 Jun 2017 Results assessing efficacy and safety of CNTX-4975 in subjects with chronic, moderate to severe osteoarthritis-associated knee pain, presented at the 18th Annual Congress of the European League Against Rheumatism.
    • 13 Jun 2017 According to a Centrexion Therapeutics media release, based on the positive data from this trial and the successful End of Phase 2 meetings with the FDA and the European authorities, the company is planning to start a Phase III trial (see profile 285871) later in 2017.
    • 13 Jun 2017 6-weeks results published in the Centrexion Therapeutics Media Release
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top